Murphy Polly A.
SEC Form 4 insider trading activity
Murphy Polly A. has filed 4 SEC Form 4 filings (4 transaction rows) across 2 companies, including AVIR, CELC, with disclosures dating back to 2026. 4 of those filings fall inside the rolling window. Most recent filing: Jun 23, 2026.
On the most recent filing, Murphy Polly A. is listed as Director at Atea Pharmaceuticals, Inc. Inside the rolling window, Murphy Polly A. reported 2 open-market purchases totaling $51K in AVIR and no open-market sales. The largest disclosed transaction in the window is a purchase of 6,100 AVIR shares on May 18, 2026, worth $25K.
Companies traded
Other insiders at AVIR
Insider Buying
$51K
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Companies
2
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Murphy Polly A. made?
Murphy Polly A. has filed 4 SEC Form 4 filings (4 transaction rows) across 2 companies, including AVIR, CELC since 2026.
Which companies does Murphy Polly A. trade?
Murphy Polly A. has filed SEC Form 4 disclosures for 2 companies, including AVIR, CELC.
When was Murphy Polly A.'s most recent SEC Form 4 filing?
Murphy Polly A.'s most recent SEC Form 4 filing on Tracefour is dated Jun 23, 2026.
What is Murphy Polly A.'s total buy and sell value in the current window?
Inside the rolling retention window, Murphy Polly A. bought $51K and sold $0 based on SEC Form 4 filings.
What was Murphy Polly A.'s largest disclosed transaction?
The largest disclosed transaction in the current window is a purchase of 6,100 AVIR shares on 2026-05-18, worth $25K, per SEC Form 4 filings.